| Kitsize | 12x8 |
| Method | ELISA |
| Incubationtime | 1x1h,1x45min,1x30min,1x15min |
| Standardrange | 100-10000ng/L |
| Specimen/Volumes | 50µLCSF |
| Substrate/isotope | TMB450nm |
| RegulatoryStatus: | EU:CE |
Milestoneinthediagnosisofneurodegenerativediseases
TheNF-Light®(Neurofilamentlight)ELISAallowsfast(3hours)quantificationoftheneurofilamentlightchain.Theassessmentrequiresaslittleas50µLofCSF.Neurofilamentlightisfoundtobeelevatedinneurodegenerativedisordersthatareassociatedwiththedestructionofwhitematter(substantiaalba).TypicallytheseareParkinson’sdisease(PD),Multiplesclerosis(MS)andAmyotrophiclateralsclerosis(ALS).
TheassaywasdevelopedbyUmanDiagnostics,acompanyfocusingonthedevelopmentofimmunochemicaltoolsforfastandaccuratedeterminationofneurologicalandtraumaticinjuries.TheNF-Light®(Neurofilamentlight)ELISAisexclusivelydistributedbyIBLInternational.
Neurofilamentlighthelpstodifferentiatebetweenneurodegenerativebraindisorders
NeurofilamentsarethebackboneoftheneuronalCytoskeleton.Insidetheaxons,phosphorylationanddephosphorylationoftheneurofilamentsregulate,respectively,theexpansionandcontractionofthemicrotubules.Theneurofilamentlight(NF-light)chainisthestoichiometricallymostcommonformcomparedtootherisoforms,suchasmediumandheavychains.Itisrapidlyreleasedafteraxonaldestructionandremainshighlystable(atleastfor8days,evenatroomtemperature).Moreover,itwasfoundtohavesignificantlyhigherdiseasesensitivityandspecificity.DuetothesespecialpropertiesneurofilamentlightisthepreferredMarkerforhelpingtodifferentiatebetweenneurodegenerativedisorders.
Parkinson’sdisease(PD)
TheROCcurvebelowshowsthatNF-light(redline)candifferentiateatypicalParkinsonsyndromes,suchasProgressivesupranuclearpalsy(PSP),Multiplesystematrophy(MSA)andCorticobasaldegeneration(CBD),fromParkinson’sdisease(PD)withhighsensitivity.
Multiplesclerosis(MS)
TheROCcurvebelowshowsthatNF-light(redline)hasasignificantlybetterdiscriminatorypowerthantheNF-heavychaintodiagnoseClinicallyisolatedsyndrome(CIS)andanyotherMS-subtype.
Amyotrophiclateralsclerosis(ALS)
ThegraphbelowshowsthatNF-lightcandifferentiaterapidlyprogressiveALS(PR>0.71/month)fromslowlyprogressiveALS(PR≥0.71/month)withhighstatisticalsignificance(p>0.0001).ItwasalsofoundthatNF-lightcanhelpdifferentiateALSfromotherneurodegenerativediseases(datanotshown).
